Gestational Trophoblastic Disease Market Report 2026

The gestational trophoblastic disease market size has grown steadily in recent years. It will grow from $2.16 billion in 2025 to $2.26 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to advances in gynecologic oncology, availability of hcg testing, surgical treatment adoption, increased awareness of rare pregnancy disorders, clinical oncology protocols.

The gestational trophoblastic disease market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to improved diagnostic accuracy, expansion of oncology centers, standardized treatment guidelines, increased healthcare access, focus on rare disease management. Major trends in the forecast period include improved hcg-based disease monitoring, rising use of chemotherapy in gtd management, increased focus on early diagnosis, expansion of specialized women’s oncology care, improved post-treatment surveillance.

The rising infertility rates are expected to drive the growth of the gestational trophoblastic disease market in the coming years. Infertility rates refer to the percentage of couples or individuals who are unable to conceive naturally after 12 months of regular, unprotected sexual activity. The increase in infertility is mainly attributed to advanced maternal and paternal age, as older reproductive age is linked to lower egg and sperm quality, reduced fertility, and higher risks of conception complications. Gestational trophoblastic disease, although primarily a pathological condition, can provide insights into infertility treatments by highlighting the role of trophoblastic tissue in implantation and hormonal regulation, thereby guiding interventions to improve conception outcomes. For instance, in April 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately 17.5% of adults globally - about 1 in 6 people - face infertility, emphasizing the urgent need for accessible, high-quality fertility care. Therefore, rising infertility rates are fueling the gestational trophoblastic disease market.

The increasing prevalence of cigarette smoking is expected to propel the growth of the gestational trophoblastic disease market going forward. Cigarette smoking involves inhaling smoke from burning tobacco, which contains multiple chemicals and toxins harmful to various body systems. Smoking can damage the DNA of trophoblastic cells, which form the placenta, potentially leading to abnormal cell growth and division, resulting in gestational trophoblastic disease. For instance, in October 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported that smoking rates among young people increased significantly, from 22.5% in 2022 to 40.1% in 2024. Therefore, the rise in cigarette smoking is driving the gestational trophoblastic disease market.

The growing prevalence of chronic diseases in mothers is expected to drive the growth of the gestational trophoblastic disease market going forward. Chronic diseases in mothers are long-lasting health conditions that may exist before, during, or after pregnancy, including diabetes, hypertension, heart disease, and autoimmune disorders, which can impact both maternal and fetal health. This rise is largely due to poor diet and nutrition, which contribute to obesity, hypertension, diabetes, and other metabolic disorders before and during pregnancy. Gestational trophoblastic disease can exacerbate these chronic conditions by causing hormonal imbalances and vascular complications that strain pre-existing health issues. For instance, in December 2024, the Office for Health Improvement and Disparities (OHID), a UK-based government agency, reported that 26.2% of women in early pregnancy were living with obesity, up slightly from 25.4% the previous year. Therefore, the increasing prevalence of chronic diseases in mothers is driving the gestational trophoblastic disease market.

Major companies operating in the gestational trophoblastic disease market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd.

Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gestational trophoblastic disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gestational trophoblastic disease market by increasing costs of imported chemotherapy drugs, diagnostic kits, and surgical instruments. Hospitals and specialized clinics are most affected due to reliance on imported oncology products. These tariffs increase treatment costs by raising expenses for chemotherapy administration, diagnostic confirmation, and surgical management. However, they encourage local pharmaceutical production, strengthening regional manufacturing of oncology drugs and essential treatment supplies.

The gestational trophoblastic disease market research report is one of a series of new reports that provides gestational trophoblastic disease market statistics, including gestational trophoblastic disease industry global market size, regional shares, competitors with a gestational trophoblastic disease market share, detailed gestational trophoblastic disease market segments, market trends and opportunities, and any further data you may need to thrive in the gestational trophoblastic disease industry. This gestational trophoblastic disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gestational trophoblastic disease (GTD) is a group of rare and abnormal conditions that arise from the atypical growth of trophoblastic cells, forming a tumor within the uterus after conception. Treatment for GTD typically involves uterine evacuation and monitoring of human chorionic gonadotropin (hCG) levels.

The main types of gestational trophoblastic disease include hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others. A hydatidiform mole, also called a molar pregnancy, is a rare and abnormal pregnancy condition. Treatment options include surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. These treatments are utilized by various end users, including hospitals, clinics, diagnostic centers, and others.

The gestational trophoblastic disease market consists of revenues earned by entities by providing services such as gynecology services, oncology services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational trophoblastic disease market also includes sales of medications, diagnostic tools, laboratory tests, methotrexate, etoposide, cyclophosphamide, and vincristine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.